Cargando…
Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease
Thrombosis is one of the most frequent complications affecting children with congenital heart disease (CHD). Palliative and reparative cardiac surgeries are some of the main players contributing to the thrombosis risk in this patient population. Additional risk factors related to the CHD itself (e.g...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555036/ https://www.ncbi.nlm.nih.gov/pubmed/34184214 http://dx.doi.org/10.1007/s40119-021-00228-4 |
_version_ | 1784591897901137920 |
---|---|
author | Abdelghani, Eman Cua, Clifford L. Giver, Jean Rodriguez, Vilmarie |
author_facet | Abdelghani, Eman Cua, Clifford L. Giver, Jean Rodriguez, Vilmarie |
author_sort | Abdelghani, Eman |
collection | PubMed |
description | Thrombosis is one of the most frequent complications affecting children with congenital heart disease (CHD). Palliative and reparative cardiac surgeries are some of the main players contributing to the thrombosis risk in this patient population. Additional risk factors related to the CHD itself (e.g., cardiac dysfunction, arrhythmias, and polycythemia in cyanotic cardiac disorders) can contribute to thrombogenicity alone or combined with other factors. Thrombotic complications have been recognized as a significant cause of morbidity and mortality in this patient population. Here, we provide an overview of the pathophysiology and risk factors for thrombosis as well as the indications for and use of different anticoagulation, antiplatelet, and thrombolytic agents. In addition, we describe some of most common thrombotic complications and their management in the pediatric CHD population. |
format | Online Article Text |
id | pubmed-8555036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-85550362021-11-10 Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease Abdelghani, Eman Cua, Clifford L. Giver, Jean Rodriguez, Vilmarie Cardiol Ther Review Thrombosis is one of the most frequent complications affecting children with congenital heart disease (CHD). Palliative and reparative cardiac surgeries are some of the main players contributing to the thrombosis risk in this patient population. Additional risk factors related to the CHD itself (e.g., cardiac dysfunction, arrhythmias, and polycythemia in cyanotic cardiac disorders) can contribute to thrombogenicity alone or combined with other factors. Thrombotic complications have been recognized as a significant cause of morbidity and mortality in this patient population. Here, we provide an overview of the pathophysiology and risk factors for thrombosis as well as the indications for and use of different anticoagulation, antiplatelet, and thrombolytic agents. In addition, we describe some of most common thrombotic complications and their management in the pediatric CHD population. Springer Healthcare 2021-06-29 2021-12 /pmc/articles/PMC8555036/ /pubmed/34184214 http://dx.doi.org/10.1007/s40119-021-00228-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Abdelghani, Eman Cua, Clifford L. Giver, Jean Rodriguez, Vilmarie Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease |
title | Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease |
title_full | Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease |
title_fullStr | Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease |
title_full_unstemmed | Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease |
title_short | Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease |
title_sort | thrombosis prevention and anticoagulation management in the pediatric patient with congenital heart disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555036/ https://www.ncbi.nlm.nih.gov/pubmed/34184214 http://dx.doi.org/10.1007/s40119-021-00228-4 |
work_keys_str_mv | AT abdelghanieman thrombosispreventionandanticoagulationmanagementinthepediatricpatientwithcongenitalheartdisease AT cuacliffordl thrombosispreventionandanticoagulationmanagementinthepediatricpatientwithcongenitalheartdisease AT giverjean thrombosispreventionandanticoagulationmanagementinthepediatricpatientwithcongenitalheartdisease AT rodriguezvilmarie thrombosispreventionandanticoagulationmanagementinthepediatricpatientwithcongenitalheartdisease |